# Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation

> **NCT00685061** · PHASE4 · COMPLETED · sponsor: **University of Miami** · enrollment: 90 (actual)

## Conditions studied

- Renal Transplantation

## Interventions

- **DRUG:** Thymoglobulin
- **DRUG:** Campath-1H
- **DRUG:** Daclizumab

## Key facts

- **NCT ID:** NCT00685061
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-09
- **Final completion:** 2005-09
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00685061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00685061, "Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00685061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*